These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 8931935

  • 1. Computational and molecular modeling evaluation of the structural basis for tubulin polymerization inhibition by colchicine site agents.
    ter Haar E, Rosenkranz HS, Hamel E, Day BW.
    Bioorg Med Chem; 1996 Oct; 4(10):1659-71. PubMed ID: 8931935
    [Abstract] [Full Text] [Related]

  • 2. Comparative molecular field analysis of colchicine inhibition and tubulin polymerization for combretastatins binding to the colchicine binding site on beta-tubulin.
    Brown ML, Rieger JM, Macdonald TL.
    Bioorg Med Chem; 2000 Jun; 8(6):1433-41. PubMed ID: 10896120
    [Abstract] [Full Text] [Related]

  • 3. Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin.
    Sackett DL.
    Pharmacol Ther; 1993 Aug; 59(2):163-228. PubMed ID: 8278462
    [Abstract] [Full Text] [Related]

  • 4. The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach.
    Chaudhuri AR, Seetharamalu P, Schwarz PM, Hausheer FH, Ludueña RF.
    J Mol Biol; 2000 Nov 10; 303(5):679-92. PubMed ID: 11061968
    [Abstract] [Full Text] [Related]

  • 5. Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly.
    Ducki S, Mackenzie G, Lawrence NJ, Snyder JP.
    J Med Chem; 2005 Jan 27; 48(2):457-65. PubMed ID: 15658859
    [Abstract] [Full Text] [Related]

  • 6. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones.
    Ducki S, Mackenzie G, Greedy B, Armitage S, Chabert JF, Bennett E, Nettles J, Snyder JP, Lawrence NJ.
    Bioorg Med Chem; 2009 Nov 15; 17(22):7711-22. PubMed ID: 19837594
    [Abstract] [Full Text] [Related]

  • 7. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.
    Lin CM, Singh SB, Chu PS, Dempcy RO, Schmidt JM, Pettit GR, Hamel E.
    Mol Pharmacol; 1988 Aug 15; 34(2):200-8. PubMed ID: 3412321
    [Abstract] [Full Text] [Related]

  • 8. Podophyllotoxin derivatives-tubulin complex reveals a potential binding site of tubulin polymerization inhibitors in α-tubulin adjacent to colchicine site.
    Zhao W, Shen R, Li HM, Zhong JJ, Tang YJ.
    Int J Biol Macromol; 2024 Sep 15; 276(Pt 1):133678. PubMed ID: 38971286
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and antimicrotubule activity of combretatropone derivatives.
    Janik ME, Bane SL.
    Bioorg Med Chem; 2002 Jun 15; 10(6):1895-903. PubMed ID: 11937347
    [Abstract] [Full Text] [Related]

  • 10. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach.
    Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, Day BW, Wipf P, Hamel E, Gussio R.
    J Med Chem; 2005 Sep 22; 48(19):6107-16. PubMed ID: 16162011
    [Abstract] [Full Text] [Related]

  • 11. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile.
    McGown AT, Fox BW.
    Anticancer Drug Des; 1989 Mar 22; 3(4):249-54. PubMed ID: 2930627
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
    Cushman M, Nagarathnam D, Gopal D, Chakraborti AK, Lin CM, Hamel E.
    J Med Chem; 1991 Aug 22; 34(8):2579-88. PubMed ID: 1875350
    [Abstract] [Full Text] [Related]

  • 13. Applying linear interaction energy method for binding affinity calculations of podophyllotoxin analogues with tubulin using continuum solvent model and prediction of cytotoxic activity.
    Alam MA, Naik PK.
    J Mol Graph Model; 2009 Aug 22; 27(8):930-43. PubMed ID: 19286405
    [Abstract] [Full Text] [Related]

  • 14. Oxalone and lactone moieties of podophyllotoxin exhibit properties of both the B and C rings of colchicine in its binding with tubulin.
    Gupta S, Das L, Datta AB, Poddar A, Janik ME, Bhattacharyya B.
    Biochemistry; 2006 May 23; 45(20):6467-75. PubMed ID: 16700557
    [Abstract] [Full Text] [Related]

  • 15. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin.
    Kim DY, Kim KH, Kim ND, Lee KY, Han CK, Yoon JH, Moon SK, Lee SS, Seong BL.
    J Med Chem; 2006 Sep 21; 49(19):5664-70. PubMed ID: 16970393
    [Abstract] [Full Text] [Related]

  • 16. Potent colchicine-site ligands with improved intrinsic solubility by replacement of the 3,4,5-trimethoxyphenyl ring with a 2-methylsulfanyl-6-methoxypyridine ring.
    Álvarez R, Aramburu L, Gajate C, Vicente-Blázquez A, Mollinedo F, Medarde M, Peláez R.
    Bioorg Chem; 2020 May 21; 98():103755. PubMed ID: 32200330
    [Abstract] [Full Text] [Related]

  • 17. Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhancement of inhibitory effects under suboptimal polymerization reaction conditions.
    Getahun Z, Jurd L, Chu PS, Lin CM, Hamel E.
    J Med Chem; 1992 Mar 20; 35(6):1058-67. PubMed ID: 1552500
    [Abstract] [Full Text] [Related]

  • 18. Exploring the size adaptability of the B ring binding zone of the colchicine site of tubulin with para-nitrogen substituted isocombretastatins.
    Jiménez C, Ellahioui Y, Álvarez R, Aramburu L, Riesco A, González M, Vicente A, Dahdouh A, Ibn Mansour A, Jiménez C, Martín D, Sarmiento RG, Medarde M, Caballero E, Peláez R.
    Eur J Med Chem; 2015 Jul 15; 100():210-22. PubMed ID: 26092446
    [Abstract] [Full Text] [Related]

  • 19. p,p-Dihydroxydihydrostilbenophanes related to antimitotic combretastatins. Conformational analysis and its relationship to tubulin inhibition.
    Álvarez R, López V, Mateo C, Medarde M, Peláez R.
    J Org Chem; 2014 Aug 01; 79(15):6840-57. PubMed ID: 24966024
    [Abstract] [Full Text] [Related]

  • 20. The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors.
    González M, Ellahioui Y, Álvarez R, Gallego-Yerga L, Caballero E, Vicente-Blázquez A, Ramudo L, Marín M, Sanz C, Medarde M, Pelaéz R.
    Molecules; 2019 Nov 26; 24(23):. PubMed ID: 31779228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.